Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma.
Canellos
G P
GP
Dana-Farber Cancer Institute, Boston, Massachusetts.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000628:therapy*; D002986:Clinical Trials as Topic; D016298:Hematopoietic Cell Growth Factors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D016896:Treatment Outcome
D016298:Hematopoietic Cell Growth Factors; D007155:Immunologic Factors